DUNEDIN, New Zealand – Pacific Edge (NZX, ASX: PEB) today reports successful execution of strategic initiatives to focus the company on the development of its advanced cancer diagnostic tests for inclusion in clinical guidelines
Infratil today announced a strong result for the year ended 31 March 2024, with Proportionate EBITDAF exceeding guidance. Alongside the result Infratil has provided an update on the significant investment in growth underway across the portfolio and accele
Infratil announced a strong result for the year ended 31 March 2024, with Proportionate EBITDAF exceeding guidance. Alongside the result Infratil has provided an update on the significant investment in growth underway across the portfolio and accelerating .